OTCMKTS:CYBN Cybin (CYBN) Stock Price, News & Analysis $5.98 -0.03 (-0.50%) As of 09/4/2025 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsBuy This Stock About Cybin Stock (OTCMKTS:CYBN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cybin alerts:Sign Up Key Stats Today's Range$5.93▼$6.4950-Day Range$5.98▼$9.0052-Week Range$4.81▼$13.88Volume1.13 million shsAverage Volume342,932 shsMarket Capitalization$141.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada. Read More Receive CYBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYBN Stock News HeadlinesCybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression TherapySeptember 2 at 5:24 AM | finance.yahoo.comCybin CEO to Speak at Canaccord Genuity Growth ConferenceAugust 6, 2025 | tipranks.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.September 5 at 2:00 AM | Investors Alley (Ad)Cybin Inc. Expands Market Strategy with New SEC FilingJuly 14, 2025 | tipranks.comCybin Inc. Secures $50 Million in Convertible Debenture DealJuly 10, 2025 | tipranks.comCybin Inc. Reports on Governance and ComplianceJuly 7, 2025 | tipranks.comCybin Inc. Advances Mental Health Innovations with Strategic Partnerships and Clinical ProgressJune 30, 2025 | tipranks.comCybin Secures $500 Million Financing to Boost Clinical ProgramsJune 30, 2025 | tipranks.comSee More Headlines CYBN Stock Analysis - Frequently Asked Questions How have CYBN shares performed this year? Cybin's stock was trading at $8.82 at the start of the year. Since then, CYBN stock has decreased by 32.2% and is now trading at $5.98. How do I buy shares of Cybin? Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cybin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cybin investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD) and Company Calendar Today9/04/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CYBN CIK1833141 Webwww.cybin.com Phone(866) 292-4601FaxN/AEmployees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-93.17% Return on Assets-84.68% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book31.47Miscellaneous Outstanding Shares23,590,000Free Float170,213,000Market Cap$141.07 million OptionableNot Optionable Beta0.68 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:CYBN) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYBN Stock Alerts